When to Use Aortograft vs PTFE for Dialysis Access
Aortografts (autologous saphenous vein grafts) should be preferred over PTFE when conduit material is needed for dialysis access, particularly when all upper extremity options are exhausted, due to superior secondary patency and significantly lower infection risk.
Primary Recommendation Framework
The 2019 KDOQI guidelines establish a clear hierarchy for dialysis access that should guide your decision-making 1:
- Upper extremity arteriovenous fistula (AVF) first - distal to proximal approach
- Upper extremity arteriovenous graft (AVG) when AVF not feasible
- Lower extremity AVF or AVG only when all upper extremity options exhausted and patient has anticipated long duration (>1 year) on hemodialysis
When Conduit Material is Required
When you've exhausted native vein options and need interposition graft material, autologous saphenous vein demonstrates clear superiority over PTFE 2:
Key Performance Differences:
Secondary Patency (Most Important for Morbidity):
- Saphenous vein: 63% at 12 months, 39% at 48 months (median 41.16 months)
- PTFE: 55% at 12 months, 19% at 48 months (median 13.77 months)
- This difference is statistically significant (p=0.032) 2
Infection Risk (Critical for Mortality):
- Saphenous vein has significantly lower infection incidence (p=0.0002) 2
- PTFE infection rates range 14-19% in various studies 3, 4
Primary Patency (Similar Between Both):
- Saphenous vein: 30% at 12 months, 20% at 48 months
- PTFE: 45% at 12 months, 14% at 48 months
- No significant difference (p=0.715) 2
Clinical Decision Algorithm
Use autologous saphenous vein when:
- Patient has anticipated long-term dialysis need (>1 year)
- Adequate saphenous vein available for harvest
- All upper extremity native vein options exhausted
- Patient can tolerate additional surgical procedure for vein harvest
Consider PTFE only when:
- No suitable autologous vein available
- Urgent access needed (early cannulation PTFE grafts can be used in 3-7 days vs standard 2-4 weeks) 5
- Patient cannot tolerate additional vein harvest procedure
- Short-term dialysis anticipated (<1 year before transplant)
Important Caveats
For diabetic patients and those on long-term steroids: While these conditions increase overall complication risk, they do not significantly alter the relative superiority of autologous vein over PTFE 3, 4. The infection advantage of saphenous vein becomes even more critical in these immunocompromised populations.
Location considerations: The saphenous vein advantage holds for both hemodialysis and parenteral nutrition access, with significantly higher secondary patency compared to PTFE in both applications (p=0.004 for parenteral nutrition) 2.
Serviceability rates: While PTFE shows reasonable initial patency (77% at 24 months), serviceability drops to 61% at 2 years and 38% at 3 years primarily due to infectious complications 4. This translates to more interventions, hospitalizations, and temporary catheter use—all negatively impacting quality of life and mortality risk.
The Bottom Line
Prioritize autologous saphenous vein over PTFE when conduit material is required for dialysis access. The 2.5-fold longer secondary patency and dramatically lower infection risk directly translate to reduced morbidity (fewer interventions, less catheter dependence) and mortality (fewer life-threatening infections). Reserve PTFE for situations where autologous vein is truly unavailable or contraindicated 2.